Parallel Advisors’s ImmunityBio IBRX Stock Holding History

Parallel Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$149	Buy	+17	New	+$129	﹤0.01%	3865
2026 Q1	–	Sell	-2,000	Closed	-$3.96K	–	3892
2025 Q4	$3.96K	Hold	2,000	–	–	﹤0.01%	2926
2025 Q3	$4.92K	Hold	2,000	–	–	﹤0.01%	2782
2025 Q2	$5.28K	Hold	2,000	–	–	﹤0.01%	2726
2025 Q1	$6.02K	Buy	+2,000	New	+$6.06K	﹤0.01%	2615
2023 Q4	–	Sell	-1,000	Closed	-$1.69K	–	3390
2023 Q3	$1.69K	Buy	+1,000	New	+$2.01K	﹤0.01%	2869
2022 Q4	–	Sell	-275	Closed	-$1.51K	–	3435
2022 Q3	$1K	Buy	+275	New	+$1.25K	﹤0.01%	2928

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.36B AUM 18.79% 1-Year Est. Return

Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return

Kercheville Advisors San Antonio, Texas $328M AUM 76.85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Parallel Advisors's IBRX Position: Q2 2026 in Review

Parallel Advisors opened a new position in ImmunityBio (IBRX) in Q2 2026: 17 shares worth $149. The stake represents ﹤0.01% of the portfolio and ranks #3865 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in IBRX as recently as Q4 2025.

Parallel Advisors first reported a position in IBRX in Q3 2022 and has held it in 7 quarters since. The position peaked at $6.02K in Q1 2025. 205 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Parallel Advisors held 17 shares of ImmunityBio worth $149 as of Q2 2026.
ImmunityBio was a new Parallel Advisors position in Q2 2026.
ImmunityBio made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3865 holding.
Parallel Advisors first reported a position in ImmunityBio in Q3 2022 and has held it in 7 quarters since.
Parallel Advisors's ImmunityBio position peaked at $6.02K in Q1 2025.
205 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.